Histone deacetylase inhibitors—turning epigenic mechanisms of gene regulation into tools of therapeutic intervention in malignant and other diseases

被引：0
作者：
Daniel Riester
Christian Hildmann
Andreas Schwienhorst
机构：
[1] Institute for Microbiology und Genetics,Department of Molecular Genetics and Preparative Molecular Biology
来源：
Applied Microbiology and Biotechnology | 2007年 / 75卷
关键词：
Histone deacetylase inhibitors; Epigenetics; Cancer drug design; Hydroxamates; Benzamides; Clinical trials;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Histone deacetylase inhibitors reside among the most promising targeted anticancer agents that are potent inducers of growth arrest, differentiation, and/or apoptotic cell death of transformed cells. In October 2006, the US Food and Drug Administration approved the first drug of this new class, vorinostat (1, Zolinza, Merck). Several histone deacetylase (HDAC) inhibitors more are in clinical trials. HDAC inhibitors have shown significant activity against a variety of hematological and solid tumors at doses that are well tolerated by patients, both in monotherapy as well as in combination therapy with other drugs. This paper reviews the most recent developments in HDAC inhibitor design, particularly in the context of anticancer therapy, and other possible pharmaceutical applications.
引用
收藏
页码：499 / 514
页数：15
相关论文
共 1462 条
[81]  
Kato T(2000)Suberoylanilide hydroxamic acid as a potential therapeutic agent for human breast cancer treatment Oncogene 19 5712-76
[82]  
Okauchi T(2006)Activation of the p21WAF1/CIP1 promoter independent of p53 by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through the Sp1 sites Cancer Chemother Pharmacol 58 618-8926
[83]  
Nishino N(2006)Effect of histone deacetylase inhibitor LAQ824 on antineoplastic action of 5-Aza-2′-deoxycytidine (decitabine) on human breast carcinoma cells Cancer Res 66 5409-1976
[84]  
Maeda S(2005)Histone deacetylase inhibitors suppress the inducibility of nuclear factor-kappaB by tumor necrosis factor-alpha receptor-1 down regulation Nat Med 11 71-299
[85]  
Nishino TG(2002)Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway Proc Natl Acad Sci USA 99 8921-3893
[86]  
Yoshida M(2005)A molecular mechanism of action of theophylline: induction of histone deacetylase activity to decrease inflammatory gene expression New Engl J Med 352 1967-215
[87]  
Bi G(2002)Decreased histone deacetylase activity in chronic obstructive pulmonary disease Nat Rev 1 287-59
[88]  
Jiang G(2006)Histone–deacetylase inhibitors: novel drugs for the treatment of cancer Oncogene 25 3885-1713
[89]  
Bieler A(2006)Modulation of cellular radiation responses by histone deacetylase inhibitors Neurosci Lett 392 213-3588
[90]  
Mantwill K(2006)Cytoprotective effect of histone deacetylase inhibitors against polyglutamine toxicity Circulation 113 51-161
45678910111213